Physician profile
Peter Taraschi
NPI 1780660852
$6,403.38
in general payments reported to CMS, 2019-2025
37 companies · $799 in 2025
The $799 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $491 · 2021: $642 · 2022: $1,096 · 2023: $1,494 · 2024: $864 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,156.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,201.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,072.15 | 2019-2025 | Farxiga, Breztri, Evusheld |
| Amgen INC. | $544.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $523.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $385.58 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $378.66 | 2022-2025 | |
| Pfizer INC. | $328.02 | 2019-2025 | |
| Abbvie INC. | $304.94 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.31 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $189.00 | 2019-2021 | |
| Exact Sciences Corporation | $149.92 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $129.09 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Novartis Pharmaceuticals Corporation | $126.71 | 2019-2022 | |
| Astellas Pharma US INC | $102.77 | 2019-2023 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.85 | 2020-2023 | Xifaxan |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Taraschi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.